The work of NanoRods founder and CTO is well known, with more than 3200 scientific citations. He has led the successful mass production and sale of bio-conjugated gold nanorods. NanoRods has already issued an exclusive license to Siva Therapeutics. He is also leading the efforts in working with potential customers including United Tech Corporation, General Electric and Rockwell Collins as well as distributor like Ted Pella, Inc, and Alfa Aesar.

Former President of Syntony has extensive experience with start-up, maturity and growth business environments, a unique blend of sales, marketing and ops experience in Manufacturing, Technology and Services sectors. With 30 years in business, including 10 years with IBM and GE, he has demonstrated strong people, process, and leadership skills offering strategic and tactical leadership during significant transition and growth business cycles.

Dr. Li has an extensive experience in nanotechnology research, including surface functionalization and thin film polymer coating; prior to joining NanoRods, he collaborated with one of the leading figures in chemistry, Alan Heeger, the 2000 Noble prize winner.

Mr. Goldin is the former Chief of Accounting, Reporting and Financial Policy at the Organization of American States and a Managing Partner at Goldin Group LLC. As the outsourced Chief Financial Officer, Mr. Goldin’s responsibility at NanoRods is Financial Strategy and oversight.

NanoRods is in the process of finalizing its selection for an operations manager who will be responsible for the oversight of all operational and non-scientific functions. These functions include but not limited to book keeping, administrative support and co-ordination with HR and Benefits, IT support, NanoRods accounting firm, Insurance, and Federal, State, and Local governments.

As CEO and Founder he has lead CytImmune since 1988. He is the co-inventor of the colloidal gold-based, tumortargeted nanomedicine platform technology, covered in 49 allowed and 42 pending patents. The Company’s first cancer nanomedicine, Aurimune, has been successfully tested in a Phase I advanced-stage cancer patient study, and Phase II testing in combination with approved chemotherapies is planned for Q3 2013.

CEO of Siva Therapeutics has 16 years of experience with commercialization of biotechnology products, services, and licensing, following an academic career as a professor of Bioengineering and Laboratory Medicine at the University of Washington. He managed R&D and P&L for a business unit of Thermo Fisher Scientific selling tools for drug discovery. He has led molecule oncology projects. He is responsible for overall corporate strategy at Siva.